EAM
TVTX icon

Exome Asset Management’s Travere Therapeutics TVTX Stock Holding History

Exome Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$594K Sell
20,000
-54,700
-73% -$1.64M 0.31% 52
2025
Q4 		$2.85M Buy
+74,700
New +$2.43M 1.36% 30

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Exome Asset Management's TVTX Position: Q1 2026 in Review

Exome Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 89,052 shares — an estimated $2.66M sold.

Exome Asset Management first reported a position in TVTX in Q4 2023 and held it in 7 quarters. The position peaked at $3.75M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Exome Asset Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 89,052 Travere Therapeutics shares in Q1 2026, an estimated $2.66M.
  • Exome Asset Management first reported a position in Travere Therapeutics in Q4 2023 and held it in 7 quarters.
  • Exome Asset Management's Travere Therapeutics position peaked at $3.75M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.